The sequence of many genes has been conserved during evolution, offering insights into gene function and new opportunities for research in pharmacology and drug development. The many ethical issues surrounding genetics have the potent tial to halt the genomic revolution unless society strives to understand and resolve these issues. Advances in pharmacogenomics hold significant promise for improved health care, such as by enabling clinicians to select the optimal medications and dosages for individual patients.
Download full-text PDF |
Source |
---|
Pharmacoeconomics
March 2006
Department of Community and Preventive Medicine, University of Rochester School of Medicine, Rochester, New York 14620, USA.
Background And Objective: In chronic disease, treatment effects and costs accumulate over time; hence, the choice of time horizon in cost-effectiveness analysis can be particularly important. In this article we analyse the dynamic changes in cumulative costs, effects and incremental cost effectiveness of two competing drug strategies in patients with early Parkinson's disease (PD).
Methods: Three hundred and one subjects with PD were randomised to initial pramipexole or levodopa and followed every 3 months over a 4-year period.
J Am Pharm Assoc (Wash)
October 2002
Celera Genomics, Rockville, MD, USA.
The sequence of many genes has been conserved during evolution, offering insights into gene function and new opportunities for research in pharmacology and drug development. The many ethical issues surrounding genetics have the potent tial to halt the genomic revolution unless society strives to understand and resolve these issues. Advances in pharmacogenomics hold significant promise for improved health care, such as by enabling clinicians to select the optimal medications and dosages for individual patients.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!